| |
|
|
|
| Unsafe Drugs
:: Singulair
|
SINGULAIR - On March 27, 2008, the FDA informed health care professionals and patients of possible connections between the use of Singulair and behavioral or mood changes. It is believed Singulair increases the risk of suicide and suicidal behavior. Patients on Singulair should be monitored closely by their treating physicians in order to hopefully catch any negative side effects before the patient does serious harm to themselves or others.
Singulair is Merck's (NYSE: MRK) top-selling asthma drug, but its sales have slowed recently over these safety concerns.
If you have experienced any suicidal thoughts or noticed that a loved one is suddenly acting differently, and you or that loved one is taking Singulair, the mood change may very well be caused by Singulair.
You or your loved one may be entitled to compensation if Singulair is found to be the reason for the complications and the injuries that resulted.
Unsafe drug cases are complex and costly to litigate. Experienced representation is essential, and that is exactly what we help provide. If you believe you or a loved one suffered a serious complication as a result of taking Singulair, please fill out the form below for a free evaluation.
Keywords: Singulair Lawsuit | Singulair Attorneys | Singulair Lawyers | Singulair Attorney | Singulair Lawyer
|
| Free Case Evaluation |
Use the form below to submit your case and receive a free evaluation. By submitting this form, you certify that you agree to our Terms and Conditions and want us to contact you regarding your inquiry. Required fields are marked in BOLD.
|
| Singulair In the News |
Merck: Making Money The Hard Way - IRA
Merck: Making Money The Hard WayIRAThe maker of popular drugs Singulair and Vytorin reported fourth-quarter revenue of $12.3 billion, up just 1.7 percent from 2010 revenue. Merck (NYSE:MRK) posted earnings of $1.5 billion...
More Information »
Merck & Co.'s CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha
Globe and MailMerck & Co.'s CEO Discusses Q4 2011 Results - Earnings Call TranscriptSeeking AlphaWe also have several important events this year in addition to our regulatory filings including FDA action on JANUMET...
More Information »
Healthcare Sector Review: Merck 4Q Earnings, Savient Announces Interim CEO - Wall St. Cheat Sheet
Healthcare Sector Review: Merck 4Q Earnings, Savient Announces Interim CEOWall St. Cheat SheetJohnson & Johnson (NYSE:JNJ): Makers of medical devices will double the fees they pay the FDA–to $595M–to get their products...
More Information »
Merck predicts huge sales losses upon the expiry of protection for its ... - PR Web (press release)
Merck predicts huge sales losses upon the expiry of protection for its ...PR Web (press release)... patent analysis and searching, recently published an article based on its proprietary Pipeline Patent Intelligence that...
More Information »
Earnings Preview: Merck - Seeking Alpha
Earnings Preview: MerckSeeking AlphaIn the past quarter, the company announced encouraging results for Victrelis, but negative results from its Tracer study. It did, however, receive FDA approval for its updated Vytorin...
More Information »
Drugmaker earnings to focus on big patent losses - MarketWatch
Drugmaker earnings to focus on big patent lossesMarketWatchXE) anticlotting drug Xarelto--to prevent stroke in patients with atrial fibrillation--overruling a negative opinion from an FDA reviewer. In other developments,...
More Information »
Why Big Pharma Doesn't Really Need (Or Even Want) A Pipeline - Seeking Alpha
Why Big Pharma Doesn't Really Need (Or Even Want) A PipelineSeeking AlphaMerck managed to sell $3.2 billion worth of Singulair in 2010... about 7% of its annual revenue. You get the idea - it's going to get real tough...
More Information »
Four Creepy Ways Big Pharma Peddles its Drugs - truthout
Four Creepy Ways Big Pharma Peddles its DrugstruthoutNow ads tout Cymbalta as a "non-narcotic, once daily analgesic FDA approved for three indications across four different chronic pain conditions," as if it does...
More Information »
Don't Lump AstraZeneca plc (AZN) In With Merck & Co. (MRK) and Pfizer (PFE) - SmallCap Network
Don't Lump AstraZeneca plc (AZN) In With Merck & Co. (MRK) and Pfizer (PFE)SmallCap NetworkMerck & Co. will contend with the loss of its best selling drug - Singulair - when that patent expires this year. And, all...
More Information »
Would You Take a Drug Because of Celebrity Advertising? Some Regret That They Did. - Food Consumer
Would You Take a Drug Because of Celebrity Advertising? Some Regret That They Did.Food ConsumerMerck used Olympic gold-medalist swimmer Peter Vanderkaay and NBA kid clubs to sell the asthma drug, Singulair despite its links...
More Information »
|
|
| |